The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...
The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...
The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely ...
many sold by online pharmacies, will no longer be allowed. Semaglutide, the main ingredient in Ozempic and Wegovy, is in ongoing shortage, the FDA says, and compounded versions of these drugs are ...
Compounders have a role to play in legitimate drug supply, Davis says; they periodically fill in shortfalls of FDA-approved drugs, such as a pediatric antibiotic infusion that was in short supply ...
Specialty pharmacies ... pressing the FDA to take the step for months — and is expected to impact how patients access the drugs, including how much they pay.Zepbound is FDA-approved to treat ...
“We continue to hear from pharmacies that the FDA-approved tirzepatide drugs are not attainable from wholesalers in quantities needed to meet demand by patients transitioning from compounded to ...
The Montreal-based National Bank said Friday the federal finance minister has approved the deal ... the Superintendent of Financial Institutions and the Competition Bureau. Canadian Western Bank ...